BeiGene Co.,Ltd Enrolls First Patient In Phase 1 Study Of BGB-3111
BEIJING--(BUSINESS WIRE)--BeiGene (Beijing), Co., Ltd., an innovative oncology company focused on developing targeted and immune-oncology therapeutics, today announced that it has dosed the first patient in a Phase 1 study of BGB-3111 for the treatment of cancer. BGB-3111 is an investigational, oral, highly selective and potent inhibitor of Bruton tyrosine kinase (BTK), a critical component of B-cell receptor (BCR) signaling which plays an important role in B-cell malignancies.
“We are excited to begin this first-in-human trial of BGB-3111, which we feel has the potential to be a best-in-class BTK inhibitor based on our preclinical results to date,” said Dr. Jason Yang, Senior Vice President and Head of Clinical Development at BeiGene. “With the strong support of our experienced team of investigators, we look forward to conducting this study and assessing dosing, PK and safety results, with the potential for early anti-tumor activity as we move toward the trial’s expansion phase later this year.”
Mr. Costa started his career in the pharmaceutical industry at Eli Lilly in Italy followed by 5 years at the Company’s US headquarters, where after leading the CNS Sales South Region, he headed Global Pricing and Access for the CNS portfolio.
Mr. Costa, is a highly successful senior commercial bio-pharma/'biotech' leader in Europe. He has delivered a track record across diverse products and therapeutic areas with experience gained on both sides of the Atlantic.
He holds a Bachelor’s degree in Business Administration from the University of Parma, and an MBA from SDA Bocconi in Milan. He currently resides near Zurich, Switzerland and is an active member of Help for Hope, a nonprofit organization with the mission to help children in need around the world (www.help-for-hope.com). Mr. Luigi Costa will take over as CEO on the 1st September 2014.
”We are about to enter a new and more international phase in the development of Nordic Nanovector. The Board is therefore pleased that Mr. Luigi Costa has accepted to take over the helm as CEO and take the Company to its new phase,” says Chairman Roy H. Larsen on behalf of the Board. ”We see this as yet another professional acknowledgement of the Company and its product Betalutin’s future potential.”
”We are grateful for Jan A. Alfheim’s personal commitment and contributions as CEO in building up the organization of the Company in the first years of its lifetime” says Roy H. Larsen.
About Nordic Nanovector AS
Nordic Nanovector AS is a privately held company established in 2009. The company is based in Norway and has offices and laboratories in Oslo. The company is developing novel innovative anticancer radioimmunotherapeutics to treat non-Hodgkin Lymphoma (NHL) and other hematological malignancies.
About Betalutin
Betalutin™, is a pharmaceutical product candidate consisting of a radionuclide conjugated to a tumor seeking carrier/antibody, which can be used for irradiation of malignant metastasized tumors with minimal damage to nearby healthy normal tissue. This technology aims to prolong and improve the quality of life of people who suffer from non-Hodgkin Lymphoma (NHL).
This information was brought to you by Cision http://news.cision.com
Contacts
Nordic Nanovector AS
Roy H. Larsen
Chairman of the Board
Phone: ( 47) 22 18 33 02
Cell: ( 47) 92 01 64 87
E-mail: sciencons@gmail.com
Help employers find you! Check out all the jobs and post your resume.